Prospective evaluation of hemostatic predictors of subacute stent thrombosis after coronary Palmaz-Schatz stenting

Medizinische Klinik, Technischen Universitat Munchen, Germany.

OBJECTIVES. This study sought to investigate hemostatic predictors of subacute occlusive coronary stent thrombosis. BACKGROUND. Better hemostatic monitoring may improve antithrombotic therapy after stenting. METHODS. In 140 consecutive patients undergoing Palmaz-Schatz stent implantation for suboptimal angioplasty results, we obtained serial blood samples immediately before and daily for 12 days after stenting. We prospectively tested the hypothesis that subacute stent thrombosis was more frequent if the surface expression of the inducible fibrinogen receptor on platelets (flow cytometry) or the concentration of plasma fibrinogen or that of the prothrombin fragments F1 + 2 before stent implantation exceeded the 75th percentile of the entire study cohort. RESULTS. All five stent occlusions encountered during the study occurred in patients with platelet fibrinogen receptor expression above the 75th percentile. Thus, the rate of stent occlusion differed significantly between the groups defined by platelet fibrinogen receptor expression (14.3% vs. 0%, p = 0.0008). In both the group with fibrinogen concentration and that with F1 + 2 concentration above the 75th percentile, three stent occlusions occurred. Between the groups defined by these variables, the rate of stent occlusion did not differ significantly (8.6% vs. 1.9%, p = 0.10). Logistic regression analysis, including angiographic and hemostatic variables, confirmed platelet fibrinogen receptor expression as an independent predictor of stent occlusion (p = 0.020). Stent occlusion could not be predicted by the time course of any of the hemostatic variables. CONCLUSIONS. Platelet fibrinogen receptor expression is an independent predictor of subacute stent occlusion. However, fibrinogen and F1 + 2 concentrations do not show a strong relation to the risk of stent occlusion.

This article has been cited by other articles:

				Z. Motovska and P. Widimsky Clopidogrel Before Elective Percutaneous Coronary Intervention J. Clin. Pharmacol., April 1, 2010; 50(4): 373 - 379. [Abstract] [Full Text] [PDF]

				D. J. Kereiakes and P. A. Gurbel Peri-Procedural Platelet Function and Platelet Inhibition in Percutaneous Coronary Intervention J. Am. Coll. Cardiol. Intv., April 1, 2008; 1(2): 111 - 121. [Abstract] [Full Text] [PDF]

				Z. N. Kon, E. N. Brown, R. Tran, A. Joshi, B. Reicher, M. C. Grant, S. Kallam, N. Burris, I. Connerney, D. Zimrin, et al. Simultaneous hybrid coronary revascularization reduces postoperative morbidity compared with results from conventional off-pump coronary artery bypass. J. Thorac. Cardiovasc. Surg., February 1, 2008; 135(2): 367 - 375. [Abstract] [Full Text] [PDF]

				F. Krotz, H. Y. Sohn, T. Gloe, S. Zahler, T. Riexinger, T. M. Schiele, B. F. Becker, K. Theisen, V. Klauss, and U. Pohl NAD(P)H oxidase-dependent platelet superoxide anion release increases platelet recruitment Blood, July 18, 2002; 100(3): 917 - 924. [Abstract] [Full Text] [PDF]

				W. B. Batchelor, K. W. Mahaffey, P. B. Berger, E. Deutsch, S. Meier, V. Hasselblad, E. T. Fry, P. S. Teirstein, A. M. Ross, C. A. Binanay, et al. A randomized, placebo-controlled trial of enoxaparin after high-risk coronary stenting: the ATLAST trial J. Am. Coll. Cardiol., November 15, 2001; 38(6): 1608 - 1613. [Abstract] [Full Text] [PDF]

				E. Atalar, K. Aytemir, I. Haznedaroglu, S. Aksoyek, K. Ovunc,, S. Kirazli, and F. Ozmen Platelet and Leukocyte Deactivation After Intracoronary Stent Placement in Patients Receiving Combined Antiplatelet Therapy Clinical and Applied Thrombosis/Hemostasis, April 1, 2001; 7(2): 116 - 121. [Abstract] [PDF]

				A. Kastrati, W. Koch, M. Gawaz, J. Mehilli, C. Bottiger, K. Schomig, N. von Beckerath, and A. Schomig PlA polymorphism of glycoprotein IIIa and risk of adverse events after coronary stent placement J. Am. Coll. Cardiol., July 1, 2000; 36(1): 84 - 89. [Abstract] [Full Text] [PDF]

				N. von Beckerath, W. Koch, J. Mehilli, C. Bottiger, A. Schomig, and A. Kastrati Glycoprotein Ia gene C807T polymorphism and risk for major adverse cardiac events within the first 30 days after coronary artery stenting Blood, June 1, 2000; 95(11): 3297 - 3301. [Abstract] [Full Text] [PDF]

				J. Dirschinger, A. Kastrati, F.-J. Neumann, P. Boekstegers, S. Elezi, J. Mehilli, H. Schuhlen, J. Pache, E. Alt, R. Blasini, et al. Influence of Balloon Pressure During Stent Placement in Native Coronary Arteries on Early and Late Angiographic and Clinical Outcome : A Randomized Evaluation of High-Pressure Inflation Circulation, August 31, 1999; 100(9): 918 - 923. [Abstract] [Full Text] [PDF]

				M. Gawaz, F.-J. Neumann, and A. Schomig Evaluation of Platelet Membrane Glycoproteins in Coronary Artery Disease : Consequences for Diagnosis and Therapy Circulation, January 12, 1999; 99(1): e1 - e11. [Full Text] [PDF]

				R. R. Azar, R. G. McKay, P. D. Thompson, J. A. Hirst, J. F. Mitchell, D. B. Fram, D. D. Waters, and F. J. Kiernan Abciximab in primary coronary angioplasty for acute myocardial infarction improves short- and medium-term outcomes J. Am. Coll. Cardiol., December 1, 1998; 32(7): 1996 - 2002. [Abstract] [Full Text] [PDF]

				A. Rodriguez, F. Ayala, V. Bernardi, O. Santaera, E. Marchand, C. Pardinas, C. Mauvecin, D. Vogel, L. C. Harrell, I. F. Palacios, et al. Optimal coronary balloon angioplasty with provisional stenting versus primary stent (OCBAS): Immediate and long-term follow-up results J. Am. Coll. Cardiol., November 1, 1998; 32(5): 1351 - 1357. [Abstract] [Full Text] [PDF]

				E. J. Topol and P. W. Serruys Frontiers in Interventional Cardiology Circulation, October 27, 1998; 98(17): 1802 - 1820. [Full Text] [PDF]

				H. J. Rupprecht, H. Darius, U. Borkowski, T. Voigtlander, B. Nowak, S. Genth, and J. Meyer Comparison of Antiplatelet Effects of Aspirin, Ticlopidine, or Their Combination After Stent Implantation Circulation, March 24, 1998; 97(11): 1046 - 1052. [Abstract] [Full Text] [PDF]

				D. J. Kereiakes, N. Kleiman, J. J. Ferguson, J. P. Runyon, T. M. Broderick, N. A. Higby, L. H. Martin, G. Hantsbarger, S. McDonald, and R. J. Anders Sustained Platelet Glycoprotein IIb/IIIa Blockade With Oral Xemilofiban in 170 Patients After Coronary Stent Deployment Circulation, August 19, 1997; 96(4): 1117 - 1121. [Abstract] [Full Text]

				T. Ammar, L. E. Scudder, and B. S. Coller In Vitro Effects of the Platelet Glycoprotein IIb/IIIa Receptor Antagonist c7E3 Fab on the Activated Clotting Time Circulation, February 4, 1997; 95(3): 614 - 617. [Abstract] [Full Text]

				R. K. Aggarwal, D. C. Ireland, M. A. Azrin, M. D. Ezekowitz, D. P. de Bono, and A. H. Gershlick Antithrombotic Potential of Polymer-Coated Stents Eluting Platelet Glycoprotein IIb/IIIa Receptor Antibody Circulation, December 15, 1996; 94(12): 3311 - 3317. [Abstract] [Full Text]

				M. Gawaz, F.-J. Neumann, I. Ott, A. May, and A. Schomig Platelet Activation and Coronary Stent Implantation: Effect of Antithrombotic Therapy Circulation, August 1, 1996; 94(3): 279 - 285. [Abstract] [Full Text]